<SEC-DOCUMENT>0001193125-18-326321.txt : 20181114
<SEC-HEADER>0001193125-18-326321.hdr.sgml : 20181114
<ACCEPTANCE-DATETIME>20181114091559
ACCESSION NUMBER:		0001193125-18-326321
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20181113
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181114
DATE AS OF CHANGE:		20181114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RESMED INC
		CENTRAL INDEX KEY:			0000943819
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				980152841
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15317
		FILM NUMBER:		181180675

	BUSINESS ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		8587462400

	MAIL ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d652852d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>November&nbsp;13, 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ResMed Inc.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-15317</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">98-0152841</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>9001 Spectrum Center Boulevard </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92123 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">836-5000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or
Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2.01 Completion of Acquisition or Disposition of Assets. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;13, 2018, ResMed Operations Inc. (&#147;<U>ResMed Operations</U>&#148;) completed its previously announced acquisition of MatrixCare Holdings,
Inc., a Delaware corporation (&#147;MatrixCare&#148;), in accordance with an Agreement and Plan of Merger (the &#147;Merger Agreement&#148;), dated November&nbsp;5, 2018, with Evolved Sub, Inc., a Delaware corporation and a wholly owned subsidiary
of ResMed Operations (&#147;<U>Merger Sub</U>&#148;), ResMed Inc. (&#147;ResMed&#148;), and OPE LGI Holdings Limited, a Canadian private company in its capacity as the agent acting on behalf of the holders of common stock and common stock options of
MatrixCare. Pursuant to the Merger Agreement, Merger Sub merged with and into MatrixCare, with MatrixCare continuing as the surviving entity and a wholly-owned subsidiary of ResMed Operations (the &#147;<U>Merger</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Merger&#146;s closing (the &#147;<U>Closing</U>&#148;), ResMed Operations paid $750&nbsp;million in cash (subject to certain adjustments set forth in
the Merger Agreement) (the &#147;<U>Merger Consideration</U>&#148;) to the holders of all issued and outstanding MatrixCare common stock and all outstanding options, warrants, and other rights to receive MaxtrixCare common stock. At the Closing,
$27.5&nbsp;million of the Merger Consideration was placed in escrow for potential indemnification claims in accordance with the indemnification provisions in the Merger Agreement. Any of the escrow funds that have not been reduced by any claims by
ResMed Operations and are not subject to any unresolved claims, will be released to the stockholders of MatrixCare at specified periods of time after the Closing in accordance with the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger
Agreement, a copy of which was filed as Exhibit 2.1 to ResMed&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) on November&nbsp;8, 2018 and is
incorporated here by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;14, 2018, ResMed issued a press release, a copy of which is attached hereto as Exhibit 99.1, announcing the completion of the Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in this Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> (including Exhibit 99.1) is being furnished and shall not be
deemed to be &#147;filed&#148; for the purpose of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), or otherwise subject to the liability of that section and shall not be incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any filing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)
<U>Financial statements of businesses acquired</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ResMed intends to file with the SEC the financial statements relating to MatrixCare under cover of
Form <FONT STYLE="white-space:nowrap">8-K/A,</FONT> no later than 71 calendar days after the date the information provided under Item 2.01 on this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> was required to be filed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <U>Pro forma financial information</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ResMed intends to
furnish with the SEC pro forma financial information relating to the Merger described in Item 2.01 above under cover of Form <FONT STYLE="white-space:nowrap">8-K/A</FONT> with the Securities and Exchange Commission no later than 71 calendar days
after the date the information provided under Item 2.01 on this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> was required to be filed. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Exhibits</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/943819/000119312518322531/d650415dex21.htm">Agreement and Plan of Merger, dated November&nbsp;
5, 2018, by and among ResMed Operations Inc., Evolved Sub, Inc., ResMed Inc., OPE LGI Holdings Limited, in its capacity as the agent acting on behalf of the holders of common stock of MatrixCare Holdings, Inc., and MatrixCare Holdings, Inc.. (incorporated
 by reference to Exhibit 2.1 to ResMed Inc.&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on November&nbsp;8, 2018).</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d652852dex991.htm">Press Release, dated November&nbsp;14, 2018.</A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934, as
amended. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>RESMED INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: November&nbsp;14, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Pendarvis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: David Pendarvis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Its: Chief administrative officer, global general counsel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">and secretary</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d652852dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g652852g1114000354258.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g652852g1114000354446.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For media:</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jayme Rubenstein</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 858.836.6798</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>news@resmed.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For investors:</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amy Wakeham</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 858.836.5000</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>investorrelations@resmed.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>ResMed Completes Acquisition of MatrixCare </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Establishes ResMed as a leader in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-hospital</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">software-as-a-service</FONT></FONT></FONT>
offerings</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Expands ResMed&#146;s SaaS offerings into additional care settings, including skilled nursing and senior
living</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Purchase price $750</I><I></I><I>&nbsp;million, accretive to
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> gross margin and <FONT STYLE="white-space:nowrap">non-GAAP</FONT> diluted earnings per share</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAN DIEGO &#150; November</B><B></B><B>&nbsp;14, 2018 &#150; </B>ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-hospital</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">software-as-a-service</FONT></FONT></FONT> (SaaS) business
solutions, today announced it has completed its $750&nbsp;million acquisition of Minnesota-based MatrixCare, a leader in software solutions for more than 15,000 providers across skilled nursing, life plan communities, senior living and private duty.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These care settings are complementary to ResMed&#146;s other SaaS offerings in home medical equipment, home health and hospice, delivered through
Brightree and HEALTHCARE<I>first, </I>acquired by ResMed in April 2016 and July 2018, respectively. ResMed will drive an integrated ecosystem of solutions across these platforms to maintain single-patient records across multiple care settings,
generate analytics and insights that can be applied to individuals and whole populations, and streamline processes across the care continuum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We&#146;re all excited to have quickly closed this important deal and can officially welcome MatrixCare to the ResMed family,&#148; said ResMed CEO Mick
Farrell. &#147;ResMed is the world&#146;s top tech-driven medical device company, and we are well on our way to being the top provider of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-hospital</FONT></FONT> software. It
all fits into our mission of changing millions of people&#146;s lives, whether it&#146;s by treating and preventing the advance of chronic disease or helping someone easily navigate
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-hospital</FONT></FONT> healthcare settings so they and their loved ones can live their best life.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MatrixCare will continue to operate as a standalone business within ResMed&#146;s SaaS portfolio, with targeted commercial, technical and operating links to
ResMed and Brightree. There will be no immediate changes to management, locations or business processes.&nbsp;MatrixCare CEO John Damgaard continues in his current role, reporting to ResMed SaaS President Raj Sodhi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The final $750&nbsp;million purchase price is subject to certain adjustments as set forth in the Merger Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ResMed </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ResMed (NYSE: RMD, ASX: RMD), a
world-leading connected health company with more than 6&nbsp;million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea,
chronic obstructive pulmonary disease and other respiratory conditions. Its <FONT STYLE="white-space:nowrap">6,000-member</FONT> team strives to improve patients&#146; quality of life, reduce the impact of chronic disease and save healthcare costs
in more than 120 countries. <U>ResMed.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MatrixCare </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Current and multi-time winner of the prestigious Best in KLAS for Long-Term Care Software award, MatrixCare is the complete solution for growing organizations
that need to successfully manage risk in care delivery across the long-term post-acute care (LTPAC) spectrum. Trusted by more than 13,000 facility-based care settings and more than 2,500 home care, home health and hospice organizations,
MatrixCare&#146;s solutions help Accountable </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Care Organizations, skilled nursing and senior living providers, life plan communities, and home health organizations to connect, collaborate and prosper as we migrate to a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-value</FONT></FONT> healthcare system. In addition to electronic health record components purpose-built for any LTPAC care-setting, MatrixCare also includes solutions to
systematically increase clinical quality: Enterprise Analytics, robust Clinical Decision Support and the industry&#146;s first Care Coordination platform to create a true, person-centric, <FONT STYLE="white-space:nowrap">e-longitudinal</FONT> health
record and enable LTPAC providers to efficiently manage the populations under their care. Visit <U>www.matrixcare.com</U> and <U>www.carecommunity.com</U> for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements contained in this
news release that are not historical facts are &#147;forward-looking&#148; statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements &#150; including statements regarding ResMed&#146;s
projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products and the integration of acquisitions &#150; are subject to risks and uncertainties that could cause actual results to
materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed&#146;s periodic reports on file with the U.S. Securities&nbsp;&amp; Exchange Commission. ResMed does not
undertake to update its forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g652852g1114000354258.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g652852g1114000354258.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( &P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WZJ>HZMI^
MD0K+J%W%;(YVJ9&QD^U0Z]K5OH&D2ZA<JS(A "+U9CP!7GUU]F^*A18'?3[V
MQ4G8_P"\1T8CGMR"*WHT.?WY:1ZLYL1B5!\D-9O9%WQ5XR\0V/B&SAT2S2YL
M)D1XW2(R"XSU 8=/\FM!_"&L2>/TU_\ M8K9A@QAW-N"[<&/'3;FNCT#1X]!
MT.UTU)&E$"GYV'))))^G)K3IRK*/NTUY7[CIT9/WJCWL[=CC+#P;?Z1K6L:Q
M:ZL\\]W')Y$4JG:';E=YSR >!QTJ.R\3WOAC2K1/&DI-[>7+1PF! V%X^]MP
M.I[<XKMZBFMX;C9YT2.4;<A90=I]1[UG[7F^/4Z(I(EHKD=%GF\.:O'H.IZC
M?ZI=W[O<0SO%\D2C^$MGCH?S[5UU1*-F4U8****D04444 %%%% 'D^I_$&+5
MYY;"\TR.329'VD9(DQGA@>Q[UWV@>%],\.)+]@C8/-C?([98@=!]*@_X0G03
MJO\ :'V,>;OW[=QV;LYSCI70UV5ZU-Q4*-TNIY^%P]6,W/$--]'V"BBBN,]
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M!^N*5QV/2[CXG>%+:XE@DU$[XG*-MB8C(.#@@<UUJ.)(U=<X8 C(QUKYFLM
M\KQ=I>DW1VMF*6[W'_5C'F,#]$Z^^:[T>/O$'BK5KB/0;C3],T^ _+->, 7'
M;KZXZ <47"QZ]17FWA'X@W4NHZEI/B)K?SK&%Y_M5N<HZ)RWZ$$8K,LO%WCC
MQG>W,WANWMK6QMVP/. Y] 2>^.PZ4[B/0-4\7:-HVK6^EWMR4O+@+Y<:H6SN
M;:.GO6Y7A'ANXO?%_P 7+6[U*$1SV@W31KT0Q#;_ .AG->[T >&>'-*?Q7\5
MKV]U&PE>P,DTY$\1"LH^1!R.>H/X4GC_ ,.R^%_&-CJNB:>3;/ME2*&$LBR(
M1N7 ' (Q^9HHI=!E[XC:9/J&IZ/XL@TZ:^TN2"/[1;A6W* 2VU@.5!#$9[$5
MG03>&]8U*TM?#O@"6YW-B<S2.@4?[P8@8]3110!L^+=3M]+OHM'UOP;OT"UC
M\NUGA=BX'&"K\8]U)S6!X,L;B7QW#J'ANUU"ST6)P\[W'3RP/F4D<-GL.311
M1U#H:'P\T^[U?Q?KNM7EK/'N@F93)&5RTI.,9_V0:QOAUX4N=7\10-J%M/'I
MUA_I$HEC959OX5&1SD@$^RT44 :GA#1[OQ3XQ\17]S!-;B>VN!&\L;* TN47
MKZ+FL?28M(\-FZT_QCX5NKF[5\PR+D9&,8'(!&1D$9ZT44N@'4Z-X<.N>$M;
MGL_"2:/=2P/%9R>:^Z92<[=K=. !GH<U1\$^-9O"OA^[T5M!OY]2CE>542(]
KP/O]QC'ITHHI@:OP=TRZ-]K6LWT,L<TK",&1"NXL2[D9]]M>M444T)G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g652852g1114000354446.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g652852g1114000354446.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ? )$# 2(  A$! Q$!_\0
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2.'LYQ3TM=K7[S:HHHKH.0__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
